European Medicines Agency concludes review of dose recommendations for anti-tuberculosis medicines used in children

 

Agrees with WHO recommendations for ethambutol, isoniazid, pyrazinamide and rifampicin

 

London, UK (February 17, 2012) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded its review of dosing recommendations from the World Health Organization (WHO) for first-line anti-tuberculosis medicines in children.

 

While the Committee acknowledged that the dosing regimen of first-line anti-tuberculosis therapies is difficult to define in children due to the limited data available and several other influencing factors, it agreed with the WHO dosing recommendations for ethambutol, isoniazid, pyrazinamide and rifampicin for children above three months as follows:

 

  • Ethambutol: 20 (15‑25) mg/kg
  • Isoniazid: 10 (10-15) mg/kg
  • Pyrazinamide: 35 (30-40) mg/kg
  • Rifampicin: 15 (10-20) mg/kg

 

The Committee acknowledged the WHO conclusion that no dosing recommendation can be made in children less than three months due to the lack of specific data.

 

The review was triggered in 2011 by the French medicines agency, following the publication of pharmacokinetic data on use of anti-tuberculosis medicines in children, which showed that weight-based dosing regimens based on corresponding adult weight might lead to sub-optimal exposure in children. The issue was recognised by the WHO in 2008, which subsequently recommended changes to dosing. The review did not address multi-resistant tuberculosis.

 

The review aims at optimising therapeutic management of the disease in the European Union and harmonising dosing in order to encourage the development of fixed dose combinations (FDC) by pharmaceutical companies. FDCs are important as they can improve how well a patient is able to follow medical advice in terms of taking medicine at the right time and taking the correct number and combination of tablets. This can be especially challenging with children.

 

While most cases of tuberculosis are limited to developing countries the disease is still prevalent in some European Member States. The average notification rate for tuberculosis in the European Union (EU) and European Economic Area (EEA) region is 16.7 per 100 000 population (2008 data).

 

This CHMP opinion will be communicated to the European Member States, so that they can take appropriate action at national level.

 

 

Notes

 

  • The review of anti-tuberculosis medicines is being conducted in the context of a formal review under Article 5(3) of Regulation (EC) No 726/2004. The assessment report for this procedure will be published in the coming weeks on the Agency’s website.
  • See more information on tuberculosis on the website of the European Centre for Disease Prevention and Control (ECDC).

 

 


European Medicines Agency, 17.02.2012 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…